Neither EMPA-REG nor CANVAS, DECLARE, and CREDENCE trials assessed the effect of SGLT2 inhibitors on neuropathy in type 2 diabetes patients, and so far, no human clinical trials addressed this association. This evidence concerns the gene SLC5A2 and neuropathy.